Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-Transplant Bortezomib and Cyclophosphamide for GVHD Prophylaxis
NCT01860170Phase 2Completed
- Sponsor
- Corewell Health
- Start
- Apr 2012
- Primary completion
- Mar 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in graft-versus-host disease (GVHD), sponsored by Corewell Health. Started Apr 2012; status: completed.
02
Drugs
bortezomib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01860170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01860170.